Low FODMAP diet for treating moderate to severe IBS
Official title: Efficacy of a Low FODMAP Diet in the Absence of Lactose Malabsorption in Moderate to Severe ROME IV IBS.
Run by Universitair Ziekenhuis Brussel · NCT05120752 · Data updated 2026-11-12
This study is testing if a low FODMAP diet can help people with moderate to severe IBS feel better by reducing symptoms like abdominal pain and bloating.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Jette, Brussels Capital) |
| Status | Recruiting |
| Started | November 2, 2021 |
| Main results expected | January 2028 |
| Study ends | January 2028 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT05120752 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 75 who meet the Rome IV criteria for IBS and have moderate symptom severity.
✕Probably not a fit
Patients with known lactose intolerance or other significant gastrointestinal disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the efficacy of a low FODMAP diet in patients with moderate to severe Irritable Bowel Syndrome (IBS) who do not have lactose malabsorption. The study aims to determine if dietary changes can alleviate symptoms associated with IBS, such as abdominal pain and bloating. Participants will be assessed based on the Rome IV criteria for IBS and will follow a specific dietary regimen to evaluate improvements in their condition. The trial is designed to provide insights into the role of diet in managing IBS symptoms.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for patients suffering from IBS by providing an effective dietary management strategy.
How similar studies have gone: Previous studies have shown beneficial effects of the low FODMAP diet in some IBS patients, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \- Patients aged 18 - 75 years; * Fulfilling the ROME IV criteria for IBS; * Moderate symptom severity as defined by a IBS-SSS \> 175; * Consumption of lactose containing products. Exclusion Criteria: * \- Clinical suspicion of an organic disorder different from LI or IBS (patients can be included when this disorder had been excluded); * Known lactose intolerance; * Known inflammatory bowel disorder; * Known major intestinal motility disorder; * Alcohol (defined as more than 14 U per week) or other substance abuse; * Active psychiatric disorder; * Known systemic or auto-immune disorder with implication for the GI system; * Prior abdominal surgery (with the exception of appendectomy); * Any prior diagnosis of cancer other than basocellular carcinoma; * Current chemotherapy; * History of gastro-enteritis in the past 8 weeks; * Intake of antibiotics, pre- or probiotics during the past 8 weeks; * Dietary supplements unless taken at a stable dose for more than 8 weeks; * Treatment with neuromodulators (one neuromodulator taken at a stable dose for more than 12 weeks is allowed); * Treatment with spasmolytic agents, opioids, loperamide, gelatin tannate or mucoprotectants during the past 8 weeks; * LFD or low FODMAP diet in the past.
Where it's running
-
UZ Brussel
Jette, Brussels Capital, Belgium Recruiting
Study contacts
- Principal investigator: Sébastien Kindt, MD — Universitair Ziekenhuis Brussel
- Study coordinator: Sébastien Kindt, MD
- Email: sebastien.kindt@uzbrussel.be
- Phone: +32 2 476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome
This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.
-
Brenipatide (LY3537031) for IBS with constipation
This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.
-
Brenipatide (LY3537031) treatment for adults with IBS‑D
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
-
Camlipixant for IBS-D and IBS-M: a test in adults
This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.
-
Defining Objective Markers of Dietary Compliance in IBS
This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.